Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Preoperative low serum MMP-9 increases 10-year relapse risk
March 31st, 2005
Preoperative low serum matrix metalloproteinase-9 immunoreactive protein levels are predictive of risk of primary breast carcinoma relapse in first 10 years of follow up, researchers report. "The immunoreactive protein for the matrix metalloproteinase-9 (MMP-9) was studied prospectively from the pre-treatment sera of breast carcinoma patients using an enzyme-linked immunoassay (ELISA). The study comprised 71 primary breast carcinoma patients treated in Oulu University Hospital, Finland, between 1988 and 1991. The median follow-up time was over 10 years," wrote Anne Talvensaari-Mattila and colleagues. "Low preoperative serum MMP-9 (<54.5 ng/ml) was...
Source: Women's Health Weekly (2005-03-31)
|
